F4‐04‐02: AGE‐RELATED CHANGES IN BASELINE COGNITIVE MEASURES IN UNIMPAIRED PSEN1 E280A MUTATION CARRIERS AND NON‐CARRIERS IN THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL
Natalia Acosta-Baena,Silvia Rios-Romenets,Claudia Muñoz,Yamile Bocanegra,Eliana Henao,Margarita Giraldo,Carlos Tobon,Kaycee Sink,Nan Hu,Heather Guthrie,Jillian Smith,William Cho,Jessica B. Langbaum,Ronald G. Thomas,Kewei Chen,Yi Su,Dhruman D. Goradia,Pradeep Thiyyagura,Paul S. VanGilder,Ji Luo,Valentina Ghisays,Wendy Lee,Michael Malek-Ahmadi,Hillary Protas,Yinghua Chen,Carole Ho,Shehnaaz Suliman,Robert Paul,Eric M. Reiman,Pierre N. Tariot,Francisco Lopera
DOI: https://doi.org/10.1016/j.jalz.2019.06.4726
2019-01-01
Abstract:Baseline data from the Alzheimer's Prevention Initiative (API) Autosomal Dominant AD (ADAD) Colombia Trial were used to a) compare cognitive measurements, b) characterize associations between cognitive decline and age, and c) estimate ages-at-onset of significant cognitive decline in cognitively unimpaired Presenilin 1 (PSEN1) E280A mutation carriers and non-carriers from the world's largest ADAD kindred. Mutation carriers in this kindred have been previously shown to progress to “pre-mild cognitive impairment” (pre-MCI), MCI and dementia at the median ages of 35, 44, and 49, respectively. Cross-sectional study of baseline trial data from 242 cognitively unimpaired 30–53 year-old mutation carriers and non-carriers were used to compare Mini-Mental State Examination (MMSE), CERAD Word Recall, Trail Making Test, Free and Cued Selective Reminding Test (FCSRT) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scores in the mutation carrier and non-carrier groups. Bivariate local polynomial regression (LOESS) was used to characterize relationships between cognitive test scores and age. Ages-at-onset of cognitive decline in the mutation carrier group were estimated based on the separation between 95% confidence interval (CI) LOESS curve bands in the carrier and non-carrier groups. In comparison with the non-carrier group, mutation carriers had significantly lower scores on several memory test scores, including CERAD Word Delayed Recall, RBANS Immediate and Delayed Memory, and FCSRT Delayed Recall scores. LOESS fits identified age-related differences, showing an inverse relationship between age and memory function in mutation carriers. Based on separation of 95% CI band, carriers had age-related declines in their memory performance, and they began to demonstrate abnormally low CERAD word delayed recall and RBANS delayed memory test score decline at the average age of 35. This study demonstrates age-related memory declines in cognitively unimpaired PSEN1 E280A mutation carriers. Memory performance becomes abnormally low at the average age of 35 years. 0, 9, and 14 years before the carriers’ previously estimated ages at onset of pre-MCI, MCI, and dementia due to AD, respectively. More analysis is required to conclude if there is an association with age (and other covariates) and cognitive performance and determine its relevance in the context of clinical trials.